Skip to main content

NASDAQ:TPIV - TapImmune Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$8.34
+0.30 (1.20%)
Get New TapImmune Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TPIV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TPIV

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for TapImmune in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $8.34.

N/A

The current consensus among 0 investment analysts is to n/a stock in TapImmune. This rating has held steady since May 2019, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/24/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/22/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/20/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/18/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/17/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/17/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/30/2018WBB SecuritiesUpgradeSpeculative Buy ➝ Buy$5.00High
i
3/16/2018WBB SecuritiesInitiated CoverageSpeculative Buy$5.00Low
i
(Data available from 5/18/2016 forward)
TapImmune logo
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.
Read More

Today's Range

Now: $8.34
$8.01
$8.40

50 Day Range

MA: $8.34
$8.34
$8.34

52 Week Range

Now: $8.34
$2.58
$13.55

Volume

100,653 shs

Average Volume

235,808 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of TapImmune?

The following Wall Street sell-side analysts have issued research reports on TapImmune in the last year:
View the latest analyst ratings for TPIV.

What is the current price target for TapImmune?

0 Wall Street analysts have set twelve-month price targets for TapImmune in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for TapImmune in the next year.
View the latest price targets for TPIV.

What is the current consensus analyst rating for TapImmune?

TapImmune currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for TPIV.

What other companies compete with TapImmune?

How do I contact TapImmune's investor relations team?

TapImmune's physical mailing address is 5 West Forsyth Street Suite 200, Jacksonville FL, 32202. The company's listed phone number is (713) 400-6400 and its investor relations email address is [email protected] The official website for TapImmune is www.tapimmune.com.